PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Principais autores: | , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2002
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC151148/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12370270/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI15634 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
